Drug Discovery and Development
Drug Discovery & Development is a B2B trade media publication delivering daily pharma and biotech news, a daily newsletter, the AI Meets Life Sci podcast, video features, sponsored Views content, and the annual Pharma 50 ranking to R&D scientists, executives, and biotech investors worldwide.
- Company typePrivate
- Founded-
- HeadquartersCleveland, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Drug Discovery and Development does
Drug Discovery & Development is a B2B digital media publication covering pharmaceutical, biotechnology, and drug discovery industry news. It is operated by Arrowfly LLC (formerly WTWH Media), a Cleveland, Ohio–based private holding company that operates more than 40 B2B media brands and more than 45 events. The publication is distributed free of charge across a multi-format platform: a flagship website at drugdiscoverytrends.com delivering daily news organized by therapeutic-area verticals (Drug Discovery, Oncology, Neurological Disease, Infectious Disease, Women in Pharma and Biotech); a daily email newsletter; the "AI Meets Life Sci" podcast distributed on Spotify, Apple Podcasts, Google Podcasts, and SoundCloud; video features with pharma executives; sponsored "Views" articles; on-site coverage of the AAPS PharmSci 360 annual meeting; and the recurring "Pharma 50" annual ranking of the world's 50 largest pharmaceutical companies.
The business model is advertising- and sponsorship-funded B2B trade media. Specific subscription pricing is not publicly disclosed, consistent with an open-access editorial model where revenue is generated through media-kit advertising, sponsored articles, conference coverage, and lead-generation programs rather than paywalls or subscriptions. Marketing and distribution operate primarily through self-serve digital channels (website, email newsletter, podcast platforms) plus organic social (LinkedIn, Facebook, X), targeting enterprise pharma and biotech buyers.
The customer base spans four segments: pharma industry professionals (R&D scientists and executives) seeking clinical-trial, regulatory, and drug-discovery coverage; biotech company founders, scientists, and investors needing biotech funding, partnership, and M&A intelligence; the academic and research community (secondary segment) consuming scientific analysis and conference coverage; and regulatory/policy professionals (secondary segment) tracking FDA approvals and compliance. The publication functions as one editorial brand inside a multi-brand B2B media portfolio; on July 13, 2026 the parent WTWH Media rebranded to Arrowfly, but the Drug Discovery & Development brand, URL, newsletter, editorial staff, and archives were preserved intact.
Drug Discovery and Development firmographics
Firmographics- Name
- Drug Discovery and Development
- Legal name
- Arrowfly LLC
- Website
- https://drugdiscoverytrends.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Drug Discovery & Development is a B2B trade media publication delivering daily pharma and biotech news, a daily newsletter, the AI Meets Life Sci podcast, video features, sponsored Views content, and the annual Pharma 50 ranking to R&D scientists, executives, and biotech investors worldwide.
- Ownership category
- akta.pro rank
Where Drug Discovery and Development is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Markets served
Drug Discovery and Development business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Distribution channels3 records
Marketing channels7 records
Drug Discovery and Development product offering
Product offeringCore offering
Drug Discovery & Development is a B2B trade media publication that delivers news, analysis, and editorial coverage of pharmaceutical and biotechnology industry developments, with particular depth in drug discovery, oncology, neurological disease, and infectious disease. The publication provides breaking news on clinical trials, FDA approvals, and corporate developments, alongside deeper analysis of AI applications in drug discovery, the annual Pharma 50 rankings, and the AI Meets Life Sci podcast. Content is distributed freely through the website, email newsletter, podcast platforms, and social channels, with monetization through advertising and sponsored Views content.
Product overview
Drug Discovery & Development is a B2B media publication that provides news, analysis, and resources for the pharmaceutical and biotech industry. The publication covers multiple therapeutic areas including Drug Discovery, Oncology, Neurological Disease, and Infectious Disease, along with Women in Pharma and Biotech content. The website serves as a hub for industry news delivery through its main editorial platform, an email newsletter, the AI Meets Life Sci podcast, video features, sponsored Views content, and annual Pharma 50 industry reports. Parent company WTWH Media rebranded to Arrowfly in July 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Discovery & Development Website B2B media publication providing news, analysis, and editorial coverage of drug discovery, pharma, and biotech industry developments across therapeutic areas including oncology, neurological disease, and infectious disease.
- Drug Discovery & Development Newsletter Email newsletter delivering the latest news and trends in drug discovery and development to subscribers on a daily basis.
- AI Meets Life Sci Podcast Podcast series exploring the transformative role of AI and ML in life sciences, featuring insights from Big Pharma, medtech OEMs, and Tech Giants.
- Video Features Video interviews and coverage featuring executives from pharma, biotech, and life sciences companies discussing industry trends and innovations.
- Views (Sponsored Content) Sponsored technical articles and case studies providing in-depth analysis on topics including drug discovery, analytics, and life sciences research.
- Pharma 50 Report Annual ranking and analysis of the 50 largest pharmaceutical companies in the world by revenue, with deep dives into company performance and industry trends.
- PharmSci 360 Coverage Coverage of the AAPS PharmSci 360 annual scientific conference, encompassing news articles and video features for pharmaceutical scientists.
Companies that use Drug Discovery and Development
Customer profileSegments4 records
Ideal customer profiles4 records
Drug Discovery and Development technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Drug Discovery and Development partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Drug Discovery and Development competitors and assessment
Company assessmentDirect peers
- Genetic Engineering & Biotechnology News (GEN): Trade publication covering biotech R&D, drug discovery, and bioprocessing; directly comparable in target audience (biotech R&D professionals) and editorial scope (drug discovery and bioprocessing news).
- BioSpace: Pharma/biotech news and career platform serving industry professionals and job-seekers; comparable in target audience (pharma R&D, biotech professionals) and in combining editorial content with a job-board / careers vertical DDD does not operate.
- FiercePharma / FierceBiotech: Established B2B pharma trade news brand covering drug development, manufacturing, and commercialization; directly comparable in audience and topic coverage to DDD, part of the Informa pharma portfolio.
- PharmaVoice: B2B pharma publication focused on industry leadership, trends, and executive perspectives; directly comparable in target audience (pharma executives and industry professionals) and editorial scope covering drug development and commercialization.
- STAT News: Subscription-based life-sciences news publication covering drug discovery, clinical trials, biotech business, and FDA/policy — directly comparable audience and editorial focus to DDD, with deeper investigative reporting resources.
- BioWorld (Clarivate): Subscription biopharma news and intelligence service covering pipeline developments, clinical trials, and regulatory news; comparable in target audience and editorial focus on drug development, with a more institutional/subscription orientation.
- BioCentury: Subscription-based B2B publication focused on biopharma strategy, pipeline analysis, and innovation; comparable in target audience (biopharma executives, investors) and in-depth analytical coverage of drug development.
- Pharmaceutical Technology: Informa-owned trade publication covering pharmaceutical development, manufacturing, and formulation — comparable in audience (pharma scientists and R&D professionals) and overlapping scope with DDD's drug discovery coverage.
- Endpoints News: Independent pharma/biotech news outlet with subscription model covering drug development, clinical trials, and industry M&A — directly comparable in audience (pharma/biotech professionals) and editorial scope (drug discovery news) to DDD, but with a subscription paywall DDD does not have.
Emerging players
- MedCity News: Healthcare and life-sciences news outlet with growing pharma/biotech coverage; partially overlapping audience (healthcare executives, pharma decision-makers) with DDD, but broader healthcare scope dilutes the drug-discovery focus.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Drug Discovery and Development social profiles
Digital presenceDrug Discovery and Development financial estimates
Financial estimateRevenue estimate
Valuation estimate
Drug Discovery and Development leadership team
Management profileNumber of profiles
Drug Discovery and Development funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Drug Discovery and Development M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Drug Discovery and Development
What does Drug Discovery and Development do?
Drug Discovery & Development is a B2B trade media publication that delivers news, analysis, and editorial coverage of pharmaceutical and biotechnology industry developments, with particular depth in drug discovery, oncology, neurological disease, and infectious disease. The publication provides breaking news on clinical trials, FDA approvals, and corporate developments, alongside deeper analysis of AI applications in drug discovery, the annual Pharma 50 rankings, and the AI Meets Life Sci podcast. Content is distributed freely through the website, email newsletter, podcast platforms, and social channels, with monetization through advertising and sponsored Views content.
Is Drug Discovery and Development a public or private company?
Drug Discovery and Development is a private company. It is classified as unknown and is currently operating.
When was Drug Discovery and Development founded?
Drug Discovery and Development was founded in -1. It employs 51 to 100 people.
Where is Drug Discovery and Development based?
Drug Discovery and Development is headquartered in Cleveland, United States, in the North America region.
Who are Drug Discovery and Development's main competitors?
Direct peers on record are Genetic Engineering & Biotechnology News (GEN), BioSpace, FiercePharma / FierceBiotech, PharmaVoice, STAT News, BioWorld (Clarivate), BioCentury, Pharmaceutical Technology and Endpoints News. MedCity News is listed as an emerging player.
Does Drug Discovery and Development have an API?
No public API is recorded for Drug Discovery and Development.